

Abatacept Biosimilar

Catalog No.: YR0045

Basic Information

Molecular Weight

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Abatacept

Isotype

Human IgG1 Fc

Immunogen

/

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Fc Protein

Recommended Dilution Buffer

1×PBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)